# Phase 3 Influenza, Human trials recruiting: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 3 for Influenza, Human that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Influenza, Human trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/influenza-human

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943390 | A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza | Boryung Biopharma Co., Ltd. | Phase 3 | Recruiting | Influenza | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943390) |
| October 22, 2026 | NCT07890454 | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult... | Sanofi | Phase 3 | Recruiting | Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization | 6,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890454) |
| October 1, 2026 | NCT07851246 | A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851246) |
| September 18, 2026 | NCT07827599 | A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in... | Hoffmann-La Roche | Phase 3 | Recruiting | Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827599) |
| September 4, 2026 | NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 54,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805707) |
| August 26, 2026 | NCT07786662 | Early Corticosteroids in Severe Influenza Pneumonia | Centre Hospitalier Régional Metz-Thionville | Phase 3 | Not yet recruiting | Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases, Hygiene | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786662) |
| June 4, 2026 | NCT07626437 | Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common... | Brainfarma Industria Química e Farmacêutica S/A | Phase 3 | Recruiting | Common Cold/Flu, Nasal Congestion, Nasal Obstruction | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626437) |
| May 22, 2026 | NCT07604103 | Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute... | University of Brawijaya | Phase 3 | Recruiting | Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604103) |
| March 20, 2026 | NCT07485855 | Influenza Vaccination Strategy for Patients With Hematologic Malignancy | Asan Medical Center | Phase 3 | Recruiting | Hematologic Neoplasms, Influenza, Immunogenicity | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485855) |
| January 20, 2026 | NCT07351500 | Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Influenza | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351500) |
| January 2, 2026 | NCT07314905 | Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | Unity Health Toronto | Phase 3 | Recruiting | Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs) | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314905) |
| November 19, 2025 | NCT07236814 | Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | Capital Medical University | Phase 3 | Recruiting | Influenza | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236814) |
| November 17, 2025 | NCT07229547 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir... | Ruijin Hospital | Phase 3 | Recruiting | Influenza | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229547) |
| September 8, 2025 | NCT07159763 | A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Recruiting | Influenza | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159763) |
| August 8, 2025 | NCT07113392 | A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Influenza | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07113392) |
| February 10, 2025 | NCT06817096 | Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza | Azidus Brasil | Phase 3 | Not yet recruiting | Covid 19, Influenza | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817096) |
| January 30, 2025 | NCT06800950 | Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 3 | Not yet recruiting | Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B, Influenza Viral Infections | 4,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06800950) |
| October 22, 2024 | NCT06653569 | Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | Sponsor not shown (see the record) | Phase 3 | Recruiting | Influenza Disease; Flu | 484 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06653569) |
| August 28, 2024 | NCT06574503 | Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Recruiting | Influenza | 748 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06574503) |
| August 27, 2024 | NCT06573008 | Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 | Recruiting | Influenza, Human | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06573008) |
| July 30, 2024 | NCT06528444 | Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza | Instituto de Investigación Sanitaria y Biomédica de Alicante | Phase 3 | Recruiting | Influenza | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06528444) |
| October 23, 2023 | NCT06094010 | A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to... | Hoffmann-La Roche | Phase 3 | Recruiting | Influenza | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094010) |
| November 22, 2022 | NCT05624450 | Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | AstraZeneca | Phase 3 | Recruiting | Viral Lung Infection and Acute Respiratory Failure | 3,527 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05624450) |
| April 3, 2019 | NCT03900988 | Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia | Chinese University of Hong Kong | Phase 3 | Recruiting | Influenza | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03900988) |
| April 13, 2016 | NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | UMC Utrecht | Phase 3 | Recruiting | Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia... | 20,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02735707) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [Jiangxi Qingfeng Pharmaceutical Co. Ltd.](https://specstream.ai/data/clinical-trials/company/jiangxi-qingfeng-pharmaceutical-co-ltd) | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Capital Medical University | 1 |
| UMC Utrecht | 1 |
| [Azidus Brasil](https://specstream.ai/data/clinical-trials/company/azidus-brasil) | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Brainfarma Industria Química e Farmacêutica S/A | 1 |
| Institute of Medical Biology, Chinese Academy of Medical Sciences | 1 |
| Ruijin Hospital | 1 |
| Instituto de Investigación Sanitaria y Biomédica de Alicante | 1 |
| Chinese University of Hong Kong | 1 |
| University of Brawijaya | 1 |
| Boryung Biopharma Co., Ltd. | 1 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 |
| Unity Health Toronto | 1 |
| Jiangxi Kvvit Pharmaceutical Co., Ltd. | 1 |
| Asan Medical Center | 1 |
| Centre Hospitalier Régional Metz-Thionville | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 7 |
| United States | 6 |
| Spain | 4 |
| Australia | 3 |
| Canada | 3 |
| France | 3 |
| Japan | 3 |
| United Kingdom | 3 |
| Poland | 3 |
| South Korea | 3 |
| Belgium | 2 |
| Colombia | 2 |
| Czechia | 2 |
| Germany | 2 |
| Hungary | 2 |
| India | 2 |
| Israel | 2 |
| Italy | 2 |
| Romania | 2 |
| Saudi Arabia | 2 |
| Switzerland | 2 |
| Argentina | 2 |
| Brazil | 2 |
| Bulgaria | 2 |
| Hong Kong | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Grout companies in the United States](https://specstream.ai/data/businesses/grout-companies/united-states)
- [Gerontology practices in the United States](https://specstream.ai/data/businesses/gerontology-practices/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
